JP2024507324A - 移植片対宿主病の治療のための組成物および方法 - Google Patents

移植片対宿主病の治療のための組成物および方法 Download PDF

Info

Publication number
JP2024507324A
JP2024507324A JP2023544229A JP2023544229A JP2024507324A JP 2024507324 A JP2024507324 A JP 2024507324A JP 2023544229 A JP2023544229 A JP 2023544229A JP 2023544229 A JP2023544229 A JP 2023544229A JP 2024507324 A JP2024507324 A JP 2024507324A
Authority
JP
Japan
Prior art keywords
subject
gvhd
apraglutide
administered
aplaglutide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023544229A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022165204A5 (https=
JP2024507324A5 (https=
Inventor
ディミトリアドウ，ヴィオレッタ
エヌ． ユーセフ，ナダー
Original Assignee
ベクティブバイオ エージー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベクティブバイオ エージー filed Critical ベクティブバイオ エージー
Publication of JP2024507324A publication Critical patent/JP2024507324A/ja
Publication of JPWO2022165204A5 publication Critical patent/JPWO2022165204A5/ja
Publication of JP2024507324A5 publication Critical patent/JP2024507324A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2023544229A 2021-01-28 2022-01-28 移植片対宿主病の治療のための組成物および方法 Pending JP2024507324A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163142905P 2021-01-28 2021-01-28
US63/142,905 2021-01-28
US202163248074P 2021-09-24 2021-09-24
US63/248,074 2021-09-24
PCT/US2022/014349 WO2022165204A1 (en) 2021-01-28 2022-01-28 Compositions and methods for the treatment of graft versus host disease

Publications (3)

Publication Number Publication Date
JP2024507324A true JP2024507324A (ja) 2024-02-19
JPWO2022165204A5 JPWO2022165204A5 (https=) 2025-02-05
JP2024507324A5 JP2024507324A5 (https=) 2025-02-05

Family

ID=80461100

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023544229A Pending JP2024507324A (ja) 2021-01-28 2022-01-28 移植片対宿主病の治療のための組成物および方法

Country Status (11)

Country Link
US (3) US20220233645A1 (https=)
EP (2) EP4635509A1 (https=)
JP (1) JP2024507324A (https=)
KR (1) KR20230167019A (https=)
AU (1) AU2022212119A1 (https=)
BR (1) BR112023014978A2 (https=)
CA (1) CA3206093A1 (https=)
ES (1) ES3044110T3 (https=)
IL (1) IL304675A (https=)
MX (1) MX2023008793A (https=)
WO (1) WO2022165204A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025208047A1 (en) * 2024-03-28 2025-10-02 Vectivbio Ag Glucagon-like peptide 2 (glp-2) analogs for the treatment of graft versus host disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200254065A1 (en) * 2019-02-11 2020-08-13 Opko Biologics Ltd. Long-acting glp-2 analogs

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8421271B2 (en) * 2009-08-31 2013-04-16 General Electric Company Apparatus for transferring energy using onboard power electronics and method of manufacturing same
EP2314616A1 (en) 2009-10-23 2011-04-27 Ferring B.V. Peptidic GLP-2 agonists
KR20230038187A (ko) 2020-06-09 2023-03-17 벡티브바이오 에이지 아프라글루타이드의 제조, 제형화 및 투여

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200254065A1 (en) * 2019-02-11 2020-08-13 Opko Biologics Ltd. Long-acting glp-2 analogs

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BLOOD, vol. vol. 136 (12), JPN6025047717, 17 September 2020 (2020-09-17), pages 1442 - 1455, ISSN: 0005735488 *
BLOOD, vol. vol. 136 (Supplement 1), JPN6025047716, 2020, pages 26 - 28, ISSN: 0005735489 *
J PARENTER ENTERAL NUTR, vol. vol. 43(7), JPN6025047714, 6 January 2019 (2019-01-06), pages 891 - 898, ISSN: 0005735491 *
J PHARMACOL EXP THER, vol. vol. 373(2), JPN6025047715, May 2020 (2020-05-01), pages 193 - 203, ISSN: 0005735490 *

Also Published As

Publication number Publication date
IL304675A (en) 2023-09-01
ES3044110T3 (en) 2025-11-26
AU2022212119A1 (en) 2023-08-10
AU2022212119A9 (en) 2024-05-16
EP4635509A1 (en) 2025-10-22
BR112023014978A2 (pt) 2023-11-07
EP4284410A1 (en) 2023-12-06
CA3206093A1 (en) 2022-08-04
EP4284410B1 (en) 2025-07-02
WO2022165204A1 (en) 2022-08-04
US20240123036A1 (en) 2024-04-18
US20220233645A1 (en) 2022-07-28
US20240285730A1 (en) 2024-08-29
KR20230167019A (ko) 2023-12-07
MX2023008793A (es) 2024-02-15

Similar Documents

Publication Publication Date Title
JP7445893B2 (ja) ヒトにおける固形腫瘍の処置のためのＣ．ｎｏｖｙｉ
JP2012510484A5 (https=)
US20240285730A1 (en) Compositions and methods for the treatment of graft versus host disease
US20110142953A1 (en) Combinations of immunosuppressive agents for the treatment or prevention of graft rejections
CN117460523A (zh) 用于治疗移植物抗宿主病的组合物和方法
WO2016130902A1 (en) Combination therapy using a cd19-adc and vincristine
EA051756B1 (ru) Композиции и способы лечения болезни "трансплантат против хозяина"
HK40102861B (en) Apraglutide for use in the treatment of gastrointestinal graft versus host disease
HK40102861A (en) Apraglutide for use in the treatment of gastrointestinal graft versus host disease
WO2025208047A1 (en) Glucagon-like peptide 2 (glp-2) analogs for the treatment of graft versus host disease
US10154989B2 (en) Methods of managing graft versus host disease (GvHD) using indole carboxyaldehydes or derivatives thereof
Butty et al. Chronic lymphocytic leukemia–associated membranous glomerulopathy: Remission with fludarabine
CN105916517A (zh) 用于治疗或缓解高龄或晚期癌症患者的药物组合物
Bakr et al. Optimizing immunosuppressive regimens among living-donor renal transplant recipients
US20250387371A1 (en) Compositions and formulation methods for sustained local release of antifibrotics
Ołdakowska-Jedynak et al. Successful reversal of acute vascular rejection and cyclosporine-associated nephrotoxicity in renal allograft with combined sirolimus and mycophenolate mofetil as immunotherapy
Raida et al. Allogeneic stem cell transplantation after fludarabine, melphalan and thymoglobulin followed by early withdrawal of prophylactic immunosuppression could be an effective approach to patients with acute lymphoblastic leukemia
Idasiak-Piechocka et al. Efficacy and safety of low-dose chlorambucil in nephrotic patients with idiopathic membranous nephropathy
HK40124218A (zh) 延长移植物和受体存活期的组合物和方法
Raida et al. Allogeneic stem cell transplantation after fludarabine, melphalan and thymoglobulin followed by early withdrawal of prophylactic immunosuppression in patients with acute lymphoblastic leukemia-update of single center study
Petrovic et al. P978 Efficacy and safety of caspofungin in solid organ transplant recipients
Oude Lashof et al. P977 Safety and tolerability of voriconazole compared to amphotericin B followed byfiuconazole in patients with candidaemia and baseline renal insufficiency
Deeg et al. Acute graft-versus-host CHAPTER
Vozniak et al. Multi-Dose Pharmacokinetic Study of Plerixafor in a Morbidly Obese Patient with Multiple Myeloma and Dialysis-Dependent Renal Impairment
Shah Evaluation of Rapamycin for the Treatment of Autoimmune-Mediated Dry Eye in a Mouse Model of Sjögren's Syndrome

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250128

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251120

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251121

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260217

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260414